Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fight for...

    Fight for Vildagliptin: Natco goes to court against Novartis

    Farhat NasimBy Farhat NasimPublished On 2019-09-07T16:32:36+05:30  |  Updated On 2021-08-16T12:52:32+05:30

    Mumbai: Throwing an indirect challenge at patent holder Novartis, drugmaker Natco Pharma has submitted a fresh application in a Hyderabad court seeking legal opinion on its right to manufacture a generic version of popular diabetes drug Vildagliptin, based on the patent expiry of the drug on December 9, 2019.


    A major anti-diabetic drug, Vildagliptin is marketed as Galvus by Novartis. It is the first (diabetes) medicine whose end-of-patent life will be witnessed by an industry. It holds about 25% share of the gliptins market of Rs 3500 crore.


    The introduction of a generic version of the drug will cut the cost of the therapy by more than 50%, making it affordable for millions of diabetics. However, Novartis has reportedly filed 73 injunctions against various firms since 2013 to block them from launching a generic version of the drug.


    Also Read: Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors


    More than a dozen companies were restricted by Novartis in 2018 in Gujarat alone from unveiling the drug before patent expiry, implying that the patent expiry of Vildagliptin is being closely watched by competitors.


    Novartis moved Delhi high court and sought legal intervention to protect its drug against companies that even planned to launch the drug, wherein Natco Pharma submitted to the court that it will not manufacture or market the drug, till the expiry of the patent in December.


    However, Natco reportedly launched some batches of the drug on August 14. As per a recent media report by TOI, in the fresh suit, Natco has lodged a case against Novartis seeking declaratory relief under Section 34 of The Specific Relief Act, 1963 before the City Civil Court in Hyderabad on August 20.


    "The Hyderabad suit is in relation to clearance of the right to manufacture Vildagliptin which is publici juris due to expiry of Indian Patent 209534 which not only discloses but also claims Vildagliptin", sources told TOI.


    The company feels this a case that restricts the patentability of a host of secondary patents, i.e., new forms of known substances, new property or new use of known substances, use of known processes without showing any enhanced therapeutic efficacy, and admixtures without synergistic effect by the innovator, with the patent being "obvious and frivolous'".

    anti-diabeic drug blockbuster drug blood sugar Delhi high court diabetes drug diabetes in India evergreening case Galvus generic drug Hyderabad Natco Novartis patent patent case patent expiry patent issue pharma pharma news pharma news india popular diabetes medicine Vildagliptin 
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X